Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers

Alan L. Williams; Raquelle S. Newman

doi:10.1370/afm.240184

Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers

Alan L. Williams^*, Raquelle S. Newman

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Confidence in hepatitis B seroprotection for US health care workers includes a complete immunization series followed by a hepatitis B surface antigen antibody (anti-HBs) titer ≥10 mIU/mL. We compared standard hepatitis B vaccines to Heplisav-B (Dynavax Technologies Corp) as a single booster for young, healthy, previously vaccinated individuals. Participants (N = 242) had documentation of a single vaccination series and an anti-HBs titer <10 mIU/ mL. In this cohort, 1 booster achieved seropositivity for 92.7% (95% CI, 84.8%-97.2%) of the standard hepatitis B vaccine group and 99.4% (95% CI, 96.6%-100.0%) of the Heplisav-B group. Both boosters are likely to produce seropositivity in this population.

Original language	English
Pages (from-to)	162-164
Number of pages	3
Journal	Annals of Family Medicine
Volume	23
Issue number	2
DOIs	https://doi.org/10.1370/afm.240184
State	Published - 1 Mar 2025
Externally published	Yes

Keywords

antibody formation
health personnel
hepatitis B vaccines
vaccination

Access to Document

10.1370/afm.240184

Cite this

@article{c077b2b488d646239995b2ce3964c986,

title = "Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers",

abstract = "Confidence in hepatitis B seroprotection for US health care workers includes a complete immunization series followed by a hepatitis B surface antigen antibody (anti-HBs) titer ≥10 mIU/mL. We compared standard hepatitis B vaccines to Heplisav-B (Dynavax Technologies Corp) as a single booster for young, healthy, previously vaccinated individuals. Participants (N = 242) had documentation of a single vaccination series and an anti-HBs titer <10 mIU/ mL. In this cohort, 1 booster achieved seropositivity for 92.7% (95% CI, 84.8%-97.2%) of the standard hepatitis B vaccine group and 99.4% (95% CI, 96.6%-100.0%) of the Heplisav-B group. Both boosters are likely to produce seropositivity in this population.",

keywords = "antibody formation, health personnel, hepatitis B vaccines, vaccination",

author = "Williams, {Alan L.} and Newman, {Raquelle S.}",

year = "2025",

month = mar,

day = "1",

doi = "10.1370/afm.240184",

language = "English",

volume = "23",

pages = "162--164",

journal = "Annals of Family Medicine",

issn = "1544-1709",

number = "2",

}

TY - JOUR

T1 - Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers

AU - Williams, Alan L.

AU - Newman, Raquelle S.

PY - 2025/3/1

Y1 - 2025/3/1

N2 - Confidence in hepatitis B seroprotection for US health care workers includes a complete immunization series followed by a hepatitis B surface antigen antibody (anti-HBs) titer ≥10 mIU/mL. We compared standard hepatitis B vaccines to Heplisav-B (Dynavax Technologies Corp) as a single booster for young, healthy, previously vaccinated individuals. Participants (N = 242) had documentation of a single vaccination series and an anti-HBs titer <10 mIU/ mL. In this cohort, 1 booster achieved seropositivity for 92.7% (95% CI, 84.8%-97.2%) of the standard hepatitis B vaccine group and 99.4% (95% CI, 96.6%-100.0%) of the Heplisav-B group. Both boosters are likely to produce seropositivity in this population.

AB - Confidence in hepatitis B seroprotection for US health care workers includes a complete immunization series followed by a hepatitis B surface antigen antibody (anti-HBs) titer ≥10 mIU/mL. We compared standard hepatitis B vaccines to Heplisav-B (Dynavax Technologies Corp) as a single booster for young, healthy, previously vaccinated individuals. Participants (N = 242) had documentation of a single vaccination series and an anti-HBs titer <10 mIU/ mL. In this cohort, 1 booster achieved seropositivity for 92.7% (95% CI, 84.8%-97.2%) of the standard hepatitis B vaccine group and 99.4% (95% CI, 96.6%-100.0%) of the Heplisav-B group. Both boosters are likely to produce seropositivity in this population.

KW - antibody formation

KW - health personnel

KW - hepatitis B vaccines

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=105001551340&partnerID=8YFLogxK

U2 - 10.1370/afm.240184

DO - 10.1370/afm.240184

M3 - Article

AN - SCOPUS:105001551340

SN - 1544-1709

VL - 23

SP - 162

EP - 164

JO - Annals of Family Medicine

JF - Annals of Family Medicine

IS - 2

ER -